Tech Company Financing Transactions
Acorda Therapeutics Funding Round
On 3/4/2004, Acorda Therapeutics received $11.5 million in funding from Cross Atlantic Capital Partners, Easton Capital and JPMorgan Partners.
Transaction Overview
Company Name
Announced On
3/4/2004
Transaction Type
Venture Equity
Amount
$11,500,000
Round
Undisclosed
Proceeds Purpose
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
420 Saw Mill River Rd.
Ardsley, NY 10502
USA
Ardsley, NY 10502
USA
Phone
Website
Email Address
Overview
Since 1995, Acorda has been a world leading biotechnology company developing multiple sclerosis (MS) and spinal cord injury treatments (SCI).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ron Cohen
Chief Medical Officer
Burkhard Blank
Chief Operating Officer
David Lawrence
Chief Scientific Officer
Andrew Blight
VP - General Counsel
Jane Wasman
VP - Human Resources
Denise Duca
VP - Regulatory Affairs
Peter Carbone
Browse more venture capital transactions:
Prev: 3/3/2004: Mempile venture capital transaction
Next: 3/4/2004: ServiceBench venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs